Mivacron (Mivacurium Chloride)

Mivacurium chloride blocks nicotinic acetylcholine receptors at the neuromuscular junction. By competitively inhibiting acetylcholine binding, it prevents depolarization of the motor end‑plate, leading to reversible skeletal muscle paralysis without causing a depolarizing phase.

The dose of Mivacron is individualized by the prescribing clinician based on patient weight, age, surgical requirements, and monitoring of neuromuscular function. No fixed regimen is provided here; dosing must follow the prescriber’s judgment and institutional protocols.

Safety data for Mivacron in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and under close medical supervision.

To order Mivacron, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mivacron has a rapid onset and short duration, making it useful for brief procedures or as a bridge to longer‑acting agents. Compared with succinylcholine, it does not cause depolarization‑related side effects, while agents like rocuronium have a longer duration and may require reversal agents.

Mivacron should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Mivacron is administered intravenously as an injection solution. It is typically given as a bolus dose followed by optional infusion, with continuous neuromuscular monitoring to guide additional dosing and ensure adequate muscle relaxation.

Serious risks include anaphylaxis, prolonged respiratory depression or apnea, severe hypotension, and life‑threatening cardiac arrhythmias such as ventricular tachycardia. Prompt recognition and supportive measures are essential if any of these events occur.

Mivacron should be avoided in patients with known hypersensitivity to mivacurium or related compounds, those with atypical pseudocholinesterase deficiency, and individuals with severe hepatic or renal impairment unless benefits outweigh risks. Caution is also advised in patients with unstable cardiovascular conditions.